Long-acting risperidone and oral antipsychotics in unstable schizophrenia

New England Journal of Medicine

Volumn 364, Issue 9, 2011, Pages 842-851

  Rosenheck, Robert A ^a,b   Krystal, John H ^a,b   Lew, Robert ^c   Barnett, Paul G ^d   Fiore, Louis ^c   Valley, Danielle ^c   Thwin, Soe Soe ^c   Vertrees, Julia E ^e   Liang, Matthew H ^c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Massachusetts Veterans Epidemiology and Research Information Center   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e University of New Mexico   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; LONG ACTING DRUG; MOOD STABILIZER; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; EXTRAPYRAMIDAL SYMPTOM; HOSPITALIZATION; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MENTAL HEALTH SERVICE; MENTAL HOSPITAL; NEUROLOGIC DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SOCIAL STATUS; SYMPTOMATOLOGY; VIDEOCONFERENCING;

EID: 79952271716     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1005987     Document Type: Article

References (37)

1. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication in the treatment of schizophrenia. Psychiatr Serv 2003;54:508-16. (Pubitemid 36752981)
2. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29.
3. Davis JM, Matalon L, Watanabe MD, Blake L, Matalon L. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-73. (Pubitemid 24151095)
4. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotics for people with schizophrenia. Br J Psychiatry 2001;179:290-9. (Pubitemid 32996037)
5. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979;36:1283-94. (Pubitemid 11145664)
6. Miyamoto S, Duncan GE, Goff DC, Lieberman JA. Therapeutics of schizophrenia. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins, 2002:775-807.
7. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32. (Pubitemid 41070972)
8. Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20:121-30. (Pubitemid 40571509)
9. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7.
10. Lindenmayer J-P, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-9.
11. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 2009;52:S29-S36.
12. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-7. (Pubitemid 39574406)
13. Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007;68:1218-25. (Pubitemid 47395624)
14. Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry 2007;191:131-9. (Pubitemid 47204533)
15. First MB, Spitzer RL, Gibbon MB, Williams JB. Structured Clinical Interview for Axes I and II DSM IV Disorders - Patient Edition (SCID-I/P). New York: Biometrics Research Institute, New York State Psychiatric Institute, 1996.
16. Grisso T, Appelbaum PS. MacArthur Competence Assessment Tool - Treatment. Worcester: University of Massachusetts Medical Center, 1995.
17. Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004;55:997-1005. (Pubitemid 39209681)
18. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004;30:193-217.
19. Rosenheck R, Tekall J, Peters J, et al. Does participation in psychosocial treatment augment the benefit of clozapine? Arch Gen Psychiatry 1998;55:618-25.
20. Guy W. Clinical Global Impressions (CGI). In: ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:534-7.
21. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83. (Pubitemid 13132147)
22. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. (Pubitemid 18039085)
23. Ruskin PE, Reed S, Kumar R, et al. Reliability and acceptability of psychiatric diagnosis via telecommunication and audiovisual technology. Psychiatr Serv 1998;49:1086-8. (Pubitemid 28363833)
24. Derogatis LR, Spencer N. The Brief Symptom Index: administration, scoring and procedure manual. Baltimore: Johns Hopkins University Press, 1982.
25. Heinrichs DW, Hanlon ET, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
26. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-9. (Pubitemid 30173584)
27. Kaplan RM, Anderson JP. The general health policy model: an integrated approach. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:309-22.
28. Pyne JM, Sullivan G, Kaplan R, Williams DK. Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med Care 2003;41:208-17.
29. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis 1980;168:26-33. (Pubitemid 10187569)
30. Barnes TR. A rating scale for drug induced akathisia. Br J Psychiatry 1989;154:672-6. (Pubitemid 19154942)
31. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:534-7.
32. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-9.
33. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 1991;48:333-9.
34. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14:105-22. (Pubitemid 17222209)
35. Nesvåg R, Tanum L. Therapeutic drug monitoring of patients on risperidone depot. Nord J Psychiatry 2005;59:51-5. (Pubitemid 40468000)
36. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
37. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia N Engl J Med 2002;346:16-22. [Erratum, N Engl J Med 2002;346:1424.]